CN114848755B - Traditional Chinese medicine composition for inhibiting helicobacter pylori - Google Patents
Traditional Chinese medicine composition for inhibiting helicobacter pylori Download PDFInfo
- Publication number
- CN114848755B CN114848755B CN202210786141.5A CN202210786141A CN114848755B CN 114848755 B CN114848755 B CN 114848755B CN 202210786141 A CN202210786141 A CN 202210786141A CN 114848755 B CN114848755 B CN 114848755B
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- sanguisorbin
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a traditional Chinese medicine composition for inhibiting helicobacter pylori, and relates to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition prepared by extracting and compounding the active ingredients can effectively inhibit helicobacter pylori.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine composition for inhibiting helicobacter pylori.
Background
Helicobacter pylori is a spiral and microaerobic bacterium, which is the only microorganism known to exist in human stomach, and can affect digestion to cause diseases such as chronic gastritis, gastric ulcer, tumor and the like, so that the helicobacter pylori is very critical to inhibit the helicobacter pylori.
So far, there are many traditional Chinese medicine preparations capable of inhibiting helicobacter pylori, such as stomach-clearing and pain-relieving pellets, stomach-soothing capsules, and Miyou soup, and various studies have been conducted in the art for related medicines, such as documents: influence of the Miaojuan Wang, Shihuajin, Guo Jiansheng, etc. the Miaoju decoction on NF-kB expression of helicobacter pylori infectious gastritis in mice [ J ]. proceedings of traditional Chinese medicine university in Hunan, 2010, 30(3):12-13. research on the curative effect of the Miaoju decoction on helicobacter pylori (H.Pylori) related gastritis in Kunming mice and the influence thereof on NF-kB expression is carried out. The literature is as follows: song Chenxue, Zheng Jingtong, Wang Yi Bo, etc. traditional Chinese medicine in combination with standard triple therapy for treating helicobacter pylori-induced chronic non-atrophic gastritis and mechanism of action thereof [ J ] proceedings of Jilin university: in the medical edition 2016(4), the traditional Chinese medicine stomach-clearing and pain-relieving pellet is combined with a standard triple therapy to treat chronic non-atrophic gastritis induced by helicobacter pylori, and a high-throughput PCR chip technology is adopted to detect the differential expression condition of inflammation-related genes so as to clarify the action mechanism of the inflammation-related genes. The literature: residual Yao, Jiayuting, Xuxianwan, etc. based on the efficacy of the stomach-clearing and pain-relieving pellet for treating helicobacter pylori in the combined medication and clinical observation [ J ] Chinese medicine basic medicine journal, 2018, 024(010):1435-1437, the curative effect and adverse reaction of the stomach-clearing and pain-relieving pellet combined with western medicine as a remedy treatment scheme on the eradication of failed helicobacter pylori infected patients are evaluated. In addition, patent CN102370884B also discloses a traditional Chinese medicine composition for treating epigastric pain and a preparation method thereof, wherein the composition is prepared from the following raw material medicines in parts by weight: 600-650 parts of coptis chinensis, 600-650 parts of radix paeoniae alba, 200-216 parts of garden burnet, 300-326 parts of rhizoma bletillae and 200-216 parts of endothelium corneum gigeriae galli. The invention provides the application of the composition in preparing the medicament for inhibiting the helicobacter pylori.
Among a plurality of helicobacter pylori inhibiting medicines, the stomach-clearing and pain-relieving pellet has the effects of clearing stomach, purging fire, softening liver and relieving pain, is mainly used for treating epigastric pain fire depression and treating epigastric pain fire depression, but the research on the stomach-clearing and pain-relieving pellet so far mainly aims at the clinical pharmacology research of the preparation or the combined use of the preparation and other medicines, but has little and less research on related effective components in a deeper level. Therefore, it is very important to develop research on this aspect and find a Chinese medicinal composition for inhibiting helicobacter pylori with excellent effect.
Disclosure of Invention
The invention provides a traditional Chinese medicine composition for inhibiting helicobacter pylori, aiming at the problems in the prior art, and the traditional Chinese medicine composition can effectively inhibit the helicobacter pylori.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
the invention provides a traditional Chinese medicine composition, which comprises the following raw materials: coptis root, bletilla striata, endothelium corneum gigeriae galli, gallic acid, sanguisorbin I, paeoniflorin and paeonol.
Further, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 100 portions of coptis root, 40 to 80 portions of bletilla striata, 30 to 60 portions of endothelium corneum gigeriae galli, 0.2 to 0.5 portion of gallic acid, 0.2 to 0.5 portion of sanguisorbin I, 0.5 to 1.0 portion of paeoniflorin and 0.001 to 0.003 portion of paeonol.
Preferably, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 110-150 parts of coptis chinensis, 50-70 parts of bletilla striata, 35-55 parts of endothelium corneum gigeriae galli, 0.25-0.5 part of gallic acid, 0.25-0.5 part of sanguisorbin I, 0.6-1.0 part of paeoniflorin and 0.0015-0.003 part of paeonol.
Further preferably, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 120 parts of coptis chinensis, 60 parts of rhizoma bletillae, 40 parts of endothelium corneum gigeriae galli, 0.4 part of gallic acid, 0.4 part of sanguisorbin I, 0.6 part of paeoniflorin and 0.0015 part of paeonol.
Further, the weight ratio of the gallic acid to the sanguisorbin I is 1-3: 1.2-3.6; preferably 1: 1.
Further, the weight ratio of paeoniflorin to sanguisorbin I is 1-3: 1-2; preferably 1.5: 1.
Further, the invention also provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps:
(1) extracting Coptidis rhizoma and radix Paeoniae alba with water, concentrating the extractive solution, and drying to obtain extract powder;
(2) drying endothelium corneum Gigeriae Galli, grinding into powder, and mixing with extract powder, gallic acid, sanguisorbin I, paeoniflorin, and paeonol.
Further, the water extraction comprises a first water decoction and a second water decoction, wherein the first water decoction lasts for 1-3 hours, and the second water decoction lasts for 1-2 hours.
Further, the ratio of water to the total weight of the coptis chinensis and the white paeony root in the first water decoction is 8-10: 1; the ratio of water to the total weight of the coptis chinensis and the white paeony root in the second water decoction is 6-8: 1.
In some embodiments, the preparation method comprises the following steps: (1) adding water into coptis chinensis and radix paeoniae alba for extraction, specifically comprising two times of decoction, wherein the weight of the water added in the first time of decoction is 8-10 times of the total weight of the coptis chinensis and the radix paeoniae alba, the decoction time is 1-3 hours, filtering is carried out to obtain an extracting solution and decoction dregs, water is continuously added into the decoction dregs for the second time of decoction, the adding amount of the water is 6-8 times of the total weight of the coptis chinensis and the radix paeoniae alba, the decoction time is 1-2 hours, the decoction dregs and the extracting solution are obtained, and the extracting solution is combined, concentrated and dried to obtain extract powder; (2) drying endothelium corneum Gigeriae Galli, grinding into powder, and mixing with extract powder, gallic acid, sanguisorbin I, paeoniflorin, and paeonol.
Furthermore, the traditional Chinese medicine composition provided by the invention or prepared by the preparation method can be applied to preparation of medicines for inhibiting helicobacter pylori.
Further, the medicine also comprises pharmaceutically acceptable auxiliary materials.
Furthermore, the dosage form of the medicine comprises tablets, granules, capsules, paste, powder and pills.
The technical effects obtained by the invention are as follows:
the invention deeply researches the efficacy of the effective components of the traditional Chinese medicinal materials, and the traditional Chinese medicine composition finally prepared can effectively inhibit helicobacter pylori by compounding the specific effective components with the traditional Chinese medicine raw materials and utilizing the synergistic effect of the effective components. The paeoniflorin plays a key role in the composition, and a certain synergistic effect exists between the paeoniflorin and the sanguisorbin I, and between the gallic acid and the sanguisorbin I.
Detailed Description
The embodiments of the present invention are described below with reference to specific embodiments, and other advantages and effects of the present invention will be easily understood by those skilled in the art from the disclosure of the present specification. The invention is capable of other and different embodiments and of being practiced or of being carried out in various ways, and its several details are capable of modification in various respects, all without departing from the spirit and scope of the present invention.
Before the present embodiments are further described, it is to be understood that the scope of the invention is not limited to the particular embodiments described below; it is also to be understood that the terminology used in the examples is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention.
When numerical ranges are given in the examples, it is understood that both endpoints of each of the numerical ranges and any value therebetween can be selected unless the invention otherwise indicated. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
It should be noted that the raw materials used in the present invention are all common commercial products, and thus the sources thereof are not particularly limited.
Example 1
A traditional Chinese medicine composition comprises the following raw materials in parts by weight: 100 parts of coptis, 40 parts of bletilla, 30 parts of endothelium corneum gigeriae galli, 0.2 part of gallic acid, 0.2 part of sanguisorbin I, 0.5 part of paeoniflorin and 0.001 part of paeonol. The preparation method of the composition comprises the following steps: (1) adding water into coptis chinensis and radix paeoniae alba for extraction, specifically comprising two times of decoction, wherein the weight of the water added in the first time of decoction is 8 times of the total weight of the coptis chinensis and the radix paeoniae alba, the time of decoction is 1 hour, filtering is carried out to obtain an extracting solution and dregs, water is continuously added into the dregs for carrying out the second time of decoction, the adding amount of the water is 8 times of the total weight of the coptis chinensis and the radix paeoniae alba, the time of decoction is 2 hours, the dregs and the extracting solution are obtained, and the extracting solution is combined, concentrated and dried to obtain extract powder; (2) drying endothelium corneum Gigeriae Galli, grinding into powder, and mixing with extract powder, gallic acid, sanguisorbin I, paeoniflorin, and paeonol.
Example 2
A traditional Chinese medicine composition comprises the following raw materials in parts by weight: 150 parts of coptis, 80 parts of bletilla, 60 parts of endothelium corneum gigeriae galli, 0.5 part of gallic acid, 0.5 part of sanguisorbin I, 1.0 part of paeoniflorin and 0.003 part of paeonol. The preparation method of the composition comprises the following steps: (1) adding water into coptis chinensis and radix paeoniae alba for extraction, specifically comprising two times of decoction, wherein the weight of the water added in the first time of decoction is 10 times of the total weight of the coptis chinensis and the radix paeoniae alba, the time of decoction is 1 hour, filtering is carried out to obtain an extracting solution and dregs, water is continuously added into the dregs for carrying out the second time of decoction, the adding amount of the water is 6 times of the total weight of the coptis chinensis and the radix paeoniae alba, the time of decoction is 1 hour, dregs and the extracting solution are obtained, and the extracting solution is combined, concentrated and dried to obtain extract powder; (2) drying endothelium corneum Gigeriae Galli, grinding into powder, and mixing with extract powder, gallic acid, sanguisorbin I, paeoniflorin, and paeonol.
Example 3
A traditional Chinese medicine composition comprises the following raw materials in parts by weight: 120 parts of coptis chinensis, 60 parts of rhizoma bletillae, 40 parts of endothelium corneum gigeriae galli, 0.4 part of gallic acid, 0.4 part of sanguisorbin I, 0.6 part of paeoniflorin and 0.0015 part of paeonol. The preparation method of the composition comprises the following steps: (1) adding water into coptis chinensis and radix paeoniae alba for extraction, specifically comprising two times of decoction, wherein the weight of the water added in the first time of decoction is 9 times of the total weight of the coptis chinensis and the radix paeoniae alba, the time of decoction is 2 hours, filtering is carried out to obtain an extracting solution and decoction dregs, water is continuously added into the decoction dregs for carrying out the second time of decoction, the adding amount of the water is 7 times of the total weight of the coptis chinensis and the radix paeoniae alba, the time of decoction is 1.5 hours, the decoction dregs and the extracting solution are obtained, and the extracting solution is combined, concentrated and dried to obtain extract powder; (2) drying endothelium corneum Gigeriae Galli, grinding into powder, and mixing with extract powder, gallic acid, sanguisorbin I, paeoniflorin, and paeonol.
Comparative example 1
The only difference from example 1 is that gallic acid was replaced with the same amount of sanguisorbin i.
Comparative example 2
The only difference from example 1 is that sanguisorbin I was replaced with an equivalent amount of gallic acid.
Comparative example 3
The difference from the embodiment 1 is that in the formula, the weight ratio of paeoniflorin to sanguisorbin I is 1: 6 (namely, the dosages of paeoniflorin and sanguisorbin I in the formula are respectively 0.1 part and 0.6 part).
Comparative example 4
The only difference from example 2 is that paeoniflorin in the formulation was replaced with an equal amount of baicalin.
The traditional Chinese medicine composition of the invention has the effect on the negative conversion curative effect of helicobacter pylori
The test method comprises the following steps:
firstly, preparing a bacterial liquid: inoculating helicobacter pylori SS1 strain in Brookfield agar culture medium, culturing at 37 deg.C for 3 days in anaerobic environment, performing gram stain microscopic examination, determining helicobacter pylori by urokinase, peroxide and catalase test, and culturing with Brookfield broth for 3 days to obtain bacterial liquid;
molding and testing: after the Wistar rat is perfused with 5% sodium bicarbonate solution (the perfusion amount is 2 mL/rat), the Wistar rat is perfused with bacterial solution (the perfusion amount is 1.5 mL/rat) for 15min once a week for 5 times. After the molding is finished, tail blood is taken to check the anti-helicobacter pylori related antibody, and the success of molding is determined if the antibody is positive. 80 rats in each example group are respectively gazed with the traditional Chinese medicine (0.5 g/kg, the gazing dose is 1mL/100 g) in each example group for 10 days, and the same amount of normal saline is gazed in the model control group. After administration, fasting was performed for 1 day, the rats were sacrificed, the gastric cavity was cut open, 3 pieces of gastric tissues were taken, and after gastric mucosal smears, bacterial cultures, and rapid urokinase tests were performed, respectively, the number of positive was counted, three indexes simultaneously negative were used as the eradication index, the eradication rate was calculated, and the results were recorded in table 1.
TABLE 1
| Examples of the invention | Positive number of microscopic examination | Hp culture Positive number (only) | Positive value of urokinase | Eradication Rate (%) |
| Model control group | 10 | 10 | 10 | 0 |
| Example 1 | 2 | 3 | 3 | 70 |
| Example 2 | 2 | 1 | 2 | 80 |
| Example 3 | 0 | 0 | 0 | 100 |
| Comparative example 1 | 3 | 3 | 3 | 70 |
| Comparative example 2 | 5 | 6 | 5 | 40 |
| Comparative example 3 | 4 | 5 | 4 | 50 |
| Comparative example 4 | 3 | 5 | 3 | 50 |
The above table shows that the composition of the present invention can effectively inhibit helicobacter pylori, and the eradication rate of helicobacter pylori can reach more than 70% on the premise of lower dosage, wherein paeoniflorin plays a critical role in the composition, and even if the paeoniflorin is replaced by other effective components with bacteriostatic effect, such as baicalin, a good eradication effect cannot be ensured. In addition, the paeoniflorin and the sanguisorbin I have very excellent effect at a specific content. In the compound, a certain synergistic effect exists between gallic acid and sanguisorbin I.
Finally, it should be noted that the above-mentioned contents are only used for illustrating the technical solutions of the present invention, and not for limiting the protection scope of the present invention, and that the simple modifications or equivalent substitutions of the technical solutions of the present invention by those of ordinary skill in the art can be made without departing from the spirit and scope of the technical solutions of the present invention.
Claims (9)
1. A traditional Chinese medicine composition for inhibiting helicobacter pylori is characterized in that: the raw materials comprise the following components in parts by weight: 100 portions of coptis root, 40 to 80 portions of bletilla striata, 30 to 60 portions of endothelium corneum gigeriae galli, 0.2 to 0.5 portion of gallic acid, 0.2 to 0.5 portion of sanguisorbin I, 0.5 to 1.0 portion of paeoniflorin and 0.001 to 0.003 portion of paeonol.
2. The traditional Chinese medicine composition according to claim 1, characterized in that: the raw materials comprise the following components in parts by weight: 110-150 parts of coptis chinensis, 50-70 parts of bletilla striata, 35-55 parts of endothelium corneum gigeriae galli, 0.25-0.5 part of gallic acid, 0.25-0.5 part of sanguisorbin I, 0.6-1.0 part of paeoniflorin and 0.0015-0.003 part of paeonol.
3. The traditional Chinese medicine composition according to claim 2, characterized in that: the raw materials comprise the following components in parts by weight: 120 parts of coptis chinensis, 60 parts of rhizoma bletillae, 40 parts of endothelium corneum gigeriae galli, 0.4 part of gallic acid, 0.4 part of sanguisorbin I, 0.6 part of paeoniflorin and 0.0015 part of paeonol.
4. The traditional Chinese medicine composition according to claim 1, characterized in that: the weight ratio of the gallic acid to the sanguisorbin I is 1: 1.
5. The traditional Chinese medicine composition according to claim 1, characterized in that: the weight ratio of paeoniflorin to sanguisorbin I is 1.5: 1.
6. The method for preparing a Chinese medicinal composition according to any one of claims 1 to 5, wherein: the method comprises the following steps:
(1) extracting Coptidis rhizoma and radix Paeoniae alba with water, concentrating the extractive solution, and drying to obtain extract powder;
(2) drying endothelium corneum Gigeriae Galli, grinding into powder, and mixing with extract powder, gallic acid, sanguisorbin I, paeoniflorin, and paeonol.
7. The method of claim 6, wherein: the water extraction comprises a first water decoction and a second water decoction, wherein the first water decoction lasts for 1-3 hours, and the second water decoction lasts for 1-2 hours.
8. The method of claim 7, wherein: the ratio of water to the total weight of the coptis chinensis and the white paeony root in the first water decoction is 8-10: 1; the ratio of water to the total weight of the coptis chinensis and the white paeony root in the second water decoction is 6-8: 1.
9. Use of a Chinese medicinal composition as claimed in any one of claims 1 to 5 in the manufacture of a medicament for the inhibition of helicobacter pylori.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210786141.5A CN114848755B (en) | 2022-07-06 | 2022-07-06 | Traditional Chinese medicine composition for inhibiting helicobacter pylori |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210786141.5A CN114848755B (en) | 2022-07-06 | 2022-07-06 | Traditional Chinese medicine composition for inhibiting helicobacter pylori |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114848755A CN114848755A (en) | 2022-08-05 |
| CN114848755B true CN114848755B (en) | 2022-09-06 |
Family
ID=82625954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210786141.5A Active CN114848755B (en) | 2022-07-06 | 2022-07-06 | Traditional Chinese medicine composition for inhibiting helicobacter pylori |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114848755B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115531485A (en) * | 2022-10-26 | 2022-12-30 | 陕西中医药大学 | Pharmaceutical composition for treating chronic gastritis and preparation method thereof |
| CN115804803B (en) * | 2022-12-19 | 2023-09-15 | 江西汪氏蜜蜂园有限公司 | Composition for inhibiting helicobacter pylori and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101972406A (en) * | 2010-09-30 | 2011-02-16 | 张子桂 | Stomach clearing and pain relieving powder and preparation method thereof |
| CN102370884A (en) * | 2010-08-16 | 2012-03-14 | 吉林华康药业股份有限公司 | Chinese medicinal composition for treating epigastric pain and preparation method thereof |
-
2022
- 2022-07-06 CN CN202210786141.5A patent/CN114848755B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102370884A (en) * | 2010-08-16 | 2012-03-14 | 吉林华康药业股份有限公司 | Chinese medicinal composition for treating epigastric pain and preparation method thereof |
| CN101972406A (en) * | 2010-09-30 | 2011-02-16 | 张子桂 | Stomach clearing and pain relieving powder and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 基于联合用药中清胃止痛微丸治疗幽门螺杆菌的功效与临床观察;余瑶等;《中国中医基础医学杂志》;20181028;第24卷(第10期);第1435-1437页 * |
| 清胃止痛微丸治疗胃溃疡的临床研究;何良志等;《中国中西医结合杂志》;20010620;第21卷(第06期);第422-423页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114848755A (en) | 2022-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114848755B (en) | Traditional Chinese medicine composition for inhibiting helicobacter pylori | |
| CN111110824B (en) | Medicinal composition for strengthening body resistance and rescuing lung and application thereof | |
| CN101209254B (en) | New use of polyhydroxy galloyl-beta-D-glucose derivatives | |
| CN101711796B (en) | Application of scullcapflavone in preparing medicament for treating enterovirus infection | |
| CN102091134B (en) | Traditional Chinese medicinal composition for resisting multi-medicine tolerance of antibiotics | |
| CN111991480A (en) | Traditional Chinese medicine composition for preventing novel coronavirus pneumonia infection | |
| CN116459295A (en) | Pneumonia clearing prescription and application thereof | |
| CN108403858B (en) | Callicarpa nudiflora extract composition for treating hand-foot-and-mouth disease and application thereof | |
| CN101229301B (en) | Chinese traditional medicine compounds for treating urinary system infection and prostatitis | |
| CN103191167B (en) | Application of eupatorium Chinese | |
| CN113332395B (en) | Traditional Chinese medicine composition for treating type 2 diabetes and preparation method thereof | |
| CN101209271B (en) | Medicinal composition for preventing helicobacter pylori | |
| CN1104246C (en) | Fumigant lotion for treating anorectal disease and preparing process thereof | |
| CN102423384B (en) | Traditional Chinese drug preparation for treating lung cancer, and preparation method thereof | |
| CN112472763A (en) | Compound traditional Chinese medicine gel containing podophyllotoxin and preparation method thereof | |
| CN101085069B (en) | Medicine for curing beriberi | |
| CN114272254B (en) | Application of combination of glycyrrhetinic acid and paeoniflorin in treating liver injury and liver fibrosis | |
| KR101452394B1 (en) | Use of amorphophallus rivieri durieu and extract thereof in the manufacture of a medicament for treating acute, chronic bronchitis | |
| CN1981832A (en) | Use of cape-jasmine extract in treatment of chronic hepatitis B | |
| CN115025143B (en) | Preparation method and application of chaetoceros extract | |
| CN111467427B (en) | Traditional Chinese medicine composition, extract thereof and application of traditional Chinese medicine composition in preventing and treating respiratory virus infection | |
| CN115177694B (en) | Plant composite extract and preparation method and application thereof | |
| CN111568935B (en) | Application of Siberian cocklebur fruit extract in preparation of antitumor drugs | |
| CN115804803B (en) | Composition for inhibiting helicobacter pylori and preparation method thereof | |
| CN114159533B (en) | Traditional Chinese medicine composition for treating multiple drug-resistant bacterial infection and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |